Abstract
To determine the cost effectiveness of adalimumab biosimilars, an anti TNF biologic and current licensed Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe Rheumatoid Arthritis (RA). METHOD A treatment sequence age-dependent Markov model was developed to compare the cost effectiveness of adalimumab biosimilars versus JAK inhibitors (upadacitinib, filgotinib, tofacitinib and baricitinib). Model outcomes were based on 10,000 simulations with ACR20, ACR50 and ACR70 probabilities determined from SELECT COMPARE, FINCH 1, ORAL STANDARD, RA-BEAM and RA-BUILD studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
